JP2023040152A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023040152A5 JP2023040152A5 JP2023000651A JP2023000651A JP2023040152A5 JP 2023040152 A5 JP2023040152 A5 JP 2023040152A5 JP 2023000651 A JP2023000651 A JP 2023000651A JP 2023000651 A JP2023000651 A JP 2023000651A JP 2023040152 A5 JP2023040152 A5 JP 2023040152A5
- Authority
- JP
- Japan
- Prior art keywords
- hours
- primary
- lymphocytes
- contacting
- viral vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 34
- 210000001744 T-lymphocyte Anatomy 0.000 claims 28
- 239000013603 viral vector Substances 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 claims 3
- 101710089751 Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 claims 3
- 102100038192 Serine/threonine-protein kinase TBK1 Human genes 0.000 claims 3
- 101710106944 Serine/threonine-protein kinase TBK1 Proteins 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000001131 transforming effect Effects 0.000 claims 3
- 102000001284 I-kappa-B kinase Human genes 0.000 claims 2
- 108060006678 I-kappa-B kinase Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 229920002491 Diethylaminoethyl-dextran Polymers 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 102100021857 Inhibitor of nuclear factor kappa-B kinase subunit epsilon Human genes 0.000 claims 1
- 101710164304 Inhibitor of nuclear factor kappa-B kinase subunit epsilon Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 102000007327 Protamines Human genes 0.000 claims 1
- 108010007568 Protamines Proteins 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229950008679 protamine sulfate Drugs 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462023618P | 2014-07-11 | 2014-07-11 | |
| US62/023,618 | 2014-07-11 | ||
| JP2020141042A JP2020191901A (ja) | 2014-07-11 | 2020-08-24 | Ｔリンパ球へのベクター導入効率の改善方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020141042A Division JP2020191901A (ja) | 2014-07-11 | 2020-08-24 | Ｔリンパ球へのベクター導入効率の改善方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023040152A JP2023040152A (ja) | 2023-03-22 |
| JP2023040152A5 true JP2023040152A5 (enExample) | 2023-07-06 |
Family
ID=55064944
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017522459A Active JP6754761B2 (ja) | 2014-07-11 | 2015-07-10 | Ｔリンパ球へのベクター導入効率の改善方法 |
| JP2020141042A Pending JP2020191901A (ja) | 2014-07-11 | 2020-08-24 | Ｔリンパ球へのベクター導入効率の改善方法 |
| JP2023000651A Pending JP2023040152A (ja) | 2014-07-11 | 2023-01-05 | Ｔリンパ球へのベクター導入効率の改善方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017522459A Active JP6754761B2 (ja) | 2014-07-11 | 2015-07-10 | Ｔリンパ球へのベクター導入効率の改善方法 |
| JP2020141042A Pending JP2020191901A (ja) | 2014-07-11 | 2020-08-24 | Ｔリンパ球へのベクター導入効率の改善方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10982189B2 (enExample) |
| EP (2) | EP3167058B1 (enExample) |
| JP (3) | JP6754761B2 (enExample) |
| ES (2) | ES2813437T3 (enExample) |
| WO (1) | WO2016007827A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150064153A1 (en) | 2013-03-15 | 2015-03-05 | The Trustees Of Princeton University | High efficiency microfluidic purification of stem cells to improve transplants |
| CN110186835B (zh) | 2013-03-15 | 2022-05-31 | Gpb科学有限公司 | 颗粒的片上微流体处理 |
| EP3608022A1 (en) | 2013-03-15 | 2020-02-12 | The Trustees of Princeton University | Methods and devices for high throughput purification |
| ES2813437T3 (es) | 2014-07-11 | 2021-03-23 | Celgene Corp | Métodos para mejorar la eficiencia de la transducción vectorial en linfocitos T |
| US10976232B2 (en) | 2015-08-24 | 2021-04-13 | Gpb Scientific, Inc. | Methods and devices for multi-step cell purification and concentration |
| CA3074495A1 (en) | 2017-09-01 | 2019-03-07 | Gpb Scientific, Llc | Methods for preparing therapeutically active cells using microfluidics |
| DE102018100967B4 (de) | 2018-01-17 | 2019-08-14 | Immatics US, Inc. | Verfahren zur feststellung der wirksamkeit von viralen vektoren |
| DE102018010282A1 (de) | 2018-01-17 | 2019-07-18 | Immatics US, Inc. | Verfahren zur Feststellung der Wirksamkeit von viralen Vektoren |
| CN108715865B (zh) * | 2018-05-28 | 2021-09-21 | 福建师范大学 | 用于提高细胞转染效率的试剂组合物 |
| EP3999081A1 (en) | 2019-07-18 | 2022-05-25 | GPB Scientific, Inc. | Ordered processing of blood products to produce therapeutically active cells |
| CN115209996B (zh) | 2019-12-28 | 2025-09-05 | 日本瑞翁株式会社 | 用于处理颗粒和细胞的微流体盒 |
| JP2024516118A (ja) * | 2021-04-06 | 2024-04-12 | ユニセット バイオテック カンパニー リミテッド ライアビリティ カンパニー | γδ Ｔ細胞のウイルス形質導入の安定性を改善する方法及びその応用 |
| WO2023286088A1 (en) * | 2021-07-16 | 2023-01-19 | Indian Institute Of Science Education And Research Bhopal | Methods and compositions for viral vector transduction |
| CN119530302B (zh) * | 2025-01-22 | 2025-06-27 | 青岛华赛伯曼医学细胞生物有限公司 | 提高til细胞的慢病毒转导效率及转导稳定性的方法及试剂盒 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5665577A (en) | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| JP4031033B2 (ja) * | 1995-05-04 | 2008-01-09 | アメリカ合衆国 | Ｔ細胞の改良トランスフェクション法 |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US7250299B1 (en) | 1999-04-29 | 2007-07-31 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| NZ527849A (en) | 2001-02-14 | 2006-09-29 | Anthrogenesis Corp | Post-partum mammalian placenta, its use and placental stem cells therefrom |
| US20060210536A1 (en) * | 2003-04-17 | 2006-09-21 | Curt Horvath | Methods and compositions for inhibiting stat signaling pathways |
| DE602004030105D1 (de) * | 2003-05-05 | 2010-12-30 | Virxsys Corp | Erhöhte transduktion mit abc-transportersubstratenhemmern |
| EP1858332A4 (en) * | 2005-02-16 | 2011-06-22 | Lentigen Corp | LENTIVIRUS VECTORS AND ITS USE |
| GB0526255D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| DK2471904T3 (en) | 2005-12-29 | 2019-02-18 | Celularity Inc | Placenta stem cell populations |
| CA2687688C (en) * | 2007-05-23 | 2017-03-28 | Sangamo Biosciences, Inc. | Methods and compositions for increased transgene expression in t cells |
| AU2008307633C1 (en) | 2007-09-28 | 2015-04-30 | Celularity Inc. | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
| CA2743566C (en) | 2008-11-19 | 2021-11-09 | Anthrogenesis Corporation | Amnion derived adherent cells |
| WO2012009422A1 (en) | 2010-07-13 | 2012-01-19 | Anthrogenesis Corporation | Methods of generating natural killer cells |
| WO2012072096A1 (en) * | 2010-12-03 | 2012-06-07 | Biontech Ag | Method for cellular rna expression |
| EP3868888A1 (en) * | 2012-02-29 | 2021-08-25 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Retroviral transduction using poloxamers |
| WO2013154760A1 (en) * | 2012-04-11 | 2013-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| WO2014046617A1 (en) * | 2012-09-19 | 2014-03-27 | Agency For Science, Technology And Research | Compositions and methods for treating cancer |
| ES2813437T3 (es) * | 2014-07-11 | 2021-03-23 | Celgene Corp | Métodos para mejorar la eficiencia de la transducción vectorial en linfocitos T |
-
2015
- 2015-07-10 ES ES15818898T patent/ES2813437T3/es active Active
- 2015-07-10 JP JP2017522459A patent/JP6754761B2/ja active Active
- 2015-07-10 EP EP15818898.7A patent/EP3167058B1/en active Active
- 2015-07-10 ES ES20176483T patent/ES2973524T3/es active Active
- 2015-07-10 WO PCT/US2015/039892 patent/WO2016007827A1/en not_active Ceased
- 2015-07-10 US US15/325,376 patent/US10982189B2/en active Active
- 2015-07-10 EP EP20176483.4A patent/EP3750993B1/en active Active
-
2020
- 2020-08-24 JP JP2020141042A patent/JP2020191901A/ja active Pending
-
2021
- 2021-03-12 US US17/200,745 patent/US11629335B2/en active Active
-
2023
- 2023-01-05 JP JP2023000651A patent/JP2023040152A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023040152A5 (enExample) | ||
| JP2020191901A5 (enExample) | ||
| JP6353953B2 (ja) | 単一ｂ細胞培養法 | |
| US4716111A (en) | Process for producing human antibodies | |
| Barbacid et al. | gag Gene of mammalian type-C RNA tumour viruses | |
| JP2013526286A5 (enExample) | ||
| EP0827512B1 (fr) | Anticorps specifique de staphylococcus aureus et utilisations | |
| CN105543170A (zh) | 一种可刺激t细胞扩增的组合物 | |
| JP2018148915A5 (enExample) | ||
| Borrebaeek et al. | Human monoclonal antibodies produced from L-leucine methyl ester-treated and in vitro immunized peripheral blood lymphocytes | |
| AU2019217363A1 (en) | Closed-system manufacturing process for CAR-T cells | |
| Dorfman | The optimal technological approach to the development of human hybridomas | |
| JPWO2020089343A5 (enExample) | ||
| CN115819590B (zh) | 抗猪红细胞膜抗体的制备及应用 | |
| JP3219772B2 (ja) | アデノ随伴ウイルスｃａｐタンパク質を特異的に認識するモノクローナル抗体 | |
| JPS61271983A (ja) | 腫瘍会合抗原に対するヒト脾細胞の生体外免疫処置法 | |
| GB2160544A (en) | Monoclonal Antibody to HLI and its use for purifying HLI | |
| JP2518607B2 (ja) | インフルエンザａ型ウイルスｈａ抗原に対するモノクロ―ナル抗体およびその作成方法 | |
| JPH01168299A (ja) | モノクローナル抗体およびそれを産生するハイブリドーマ | |
| CN112375140A (zh) | 一种快速、大通量兔多克隆抗体体外生产方法 | |
| JP5435539B2 (ja) | 抗体産生細胞の活性化ペプチド | |
| JP3029635B2 (ja) | 抗体産生変異株の取得方法 | |
| CN114350606A (zh) | 一种富集大鼠浆细胞及建立浆细胞杂交瘤的方法 | |
| JP5246859B2 (ja) | 抗体産生細胞の誘導又は活性化方法 | |
| SU1527260A1 (ru) | Штамм гибридных культивируемых клеток животных MUS мUSсULUS, используемый дл получени моноклональных антител к @ - тимозину |